Full TitleExpanded Access Program for Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody (EAP)
This study offers access to the investigational drug belantamab mafodotin for people with multiple myeloma that has come back or continued to grow despite treatment. It is available for patients who previously received it and benefited from it as well as people with persistent multiple myeloma who have not yet received it.
Belantamab mafodotin is made up of an antibody and a chemotherapy drug. The antibody binds to the BCMA protein on multiple myeloma cells, and the chemotherapy enters the cells to kill them. The medication is given intravenously (by vein). Because belantamab mafodotin can cause eye problems as a side effect, participants in this study will also have an eye exam and be monitored for eye problems.
Who Can Join
To be eligible for this study, patients must meet several requirements, including:
- This study is open to patients who previously received belantamab mafodotin and benefited from it as well as people with persistent multiple myeloma who have not yet received it.
- Patients who have not yet received belantamab mafodotin must have multiple myeloma that persists despite at least four prior regimens of treatment.
- This study is for people age 18 and older.
For more information and to ask about eligibility for this study, please contact the office of Dr. Malin Hultcrantz at 646-608-3714.